Amneal Receives Approval for Generic Version of Ortho Evra® – Company granted 180 days of exclusivity under FDA Competitive Generic Therapy (CGT) approval pathway –
BRIDGEWATER, N.J.– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the“Company”) announced that it has received approval of an additional strength of 500 mg to its
COVID-19 has put the need for intensive care units (ICUs) and ventilators in the news every day. Ventilators help people breathe when they are unable
Now Available from Amneal: Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection AP-rated equivalent to Precedex® -Ready-to-use; no admixing required -Includes vial label hangers for efficient
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5% Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for
Now Available from Amneal: Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection AP-rated equivalent to Precedex® -Ready-to-use; no admixing required -Includes vial label hangers for efficient
Amneal Resumes Shipping of Axid® Equivalent Nizatidine Oral Solution Only oral liquid formulation available BRIDGEWATER, N.J.– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that its
Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5% Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has
Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated
It’s not Just the Depth of our Pipeline, It’s the Quality and Value it Delivers We focus on the details that build trust. Today, Amneal
